LSP is one of the largest European investment firms providing financing for life sciences and health care companies. LSP’s management has raised over EUR 2 billion ($2.3 billion) and developed more than 120 companies since it started to invest in 1988. From its offices in Amsterdam, Munich and Boston, LSP manages three distinct investment activities: LSP 6 invests in private early- to late-stage drug development and medical technology companies; LSP HEF 2 focuses on private late-stage medical technology companies with a health and economic benefit; and LSP Public targets public healthcare companies. Among LSP’s signature deals are argenx, Crucell, KuDOS, Movetis, Neuravi, Okairos, Prosensa, Qiagen and Zealand Pharma. In addition, LSP is an active contributor to the life sciences industry through roles as founder and board member of the Oncode Institute, initiator of the Dutch Venture Initiative (DVI), as well as board member of European venture capital associations, technology transfer institutes and government bodies. For more information: lspvc.com.
Cardior, Immunic, Orphazyme, Pharvaris, Atlas Genetics, Neuravi, G-Therapeutics, ViCentra...
U3 - 2008 / Jerini - 2008 / Flow Cardia - 2010 / Okairos - 2013 / Sapiens - 2014 / Prosensa - 2015 / Neuravi - 2017
Qiagen - 1996 / Rhein-Biotech - 1999 / Crucell - 2000 / deVGen - 2005 / Movetis - 2010